The Fort Worth Press - Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025

USD -
AED 3.672507
AFN 65.000291
ALL 82.302472
AMD 357.809202
ANG 1.790403
AOA 917.999875
ARS 1549.753496
AUD 1.483019
AWG 1.8
AZN 1.695071
BAM 1.7757
BBD 2.012982
BDT 124.44505
BGN 1.77347
BHD 0.37742
BIF 3001.498025
BMD 1
BND 1.288366
BOB 11.659547
BRL 5.786199
BSD 0.99941
BTN 93.823002
BWP 13.990966
BYN 3.003223
BYR 19600
BZD 2.010077
CAD 1.43023
CDF 2314.999897
CHF 0.83989
CLF 0.025392
CLP 999.349858
CNY 6.67175
CNH 6.664955
COP 3317.97
CRC 445.37243
CUC 1
CUP 23.986201
CVE 100.108947
CZK 22.199349
DJF 177.719794
DKK 6.79576
DOP 60.748576
DZD 137.03898
EGP 53.677976
ERN 15
ETB 164.058597
EUR 0.90911
FJD 2.280097
FKP 0.756558
GBP 0.758415
GEL 2.590107
GGP 0.756558
GHS 11.709483
GIP 0.756558
GMD 73.99989
GNF 8855.599437
GTQ 7.63916
GYD 209.138162
HKD 7.846125
HNL 26.880632
HRK 6.831965
HTG 130.99394
HUF 331.400499
IDR 18258.7
ILS 3.24365
IMP 0.756558
INR 93.89715
IQD 1515.309712
IRR 1913737.499047
ISK 124.359748
JEP 0.756558
JMD 158.482001
JOD 0.709033
JPY 159.536496
KES 129.969693
KGS 87.449398
KHR 4098.364377
KMF 447.000415
KPW 900.00035
KRW 1335.549942
KWD 0.31161
KYD 0.833012
KZT 444.73296
LAK 22505.595075
LBP 89510.130151
LKR 332.650884
LRD 169.925324
LSL 16.93731
LTL 2.95274
LVL 0.60489
LYD 6.457851
MAD 9.963139
MDL 18.281771
MGA 4546.321093
MKD 55.927629
MMK 2099.568705
MNT 3604.028735
MOP 8.07799
MRU 40.587408
MUR 47.809734
MVR 15.398196
MWK 1733.209252
MXN 18.56698
MYR 4.093498
MZN 63.90174
NAD 16.93731
NGN 1345.220271
NIO 36.779626
NOK 9.64499
NPR 150.11644
NZD 1.81728
OMR 0.384499
PAB 0.999532
PEN 3.408766
PGK 4.563138
PHP 63.886011
PKR 276.374515
PLN 4.001925
PYG 6202.732761
QAR 3.653729
RON 4.860198
RSD 106.911017
RUB 82.600372
RWF 1476.632544
SAR 3.763042
SBD 8.097697
SCR 13.916252
SDG 601.493572
SEK 10.097505
SGD 1.289165
SHP 0.752984
SLE 23.05065
SLL 20969.503664
SOS 571.259959
SRD 37.4535
STD 20697.981008
STN 22.241387
SVC 8.745744
SYP 13002.000337
SZL 16.932226
THB 33.906
TJS 9.210795
TMT 3.5
TND 3.021631
TOP 2.40776
TRY 50.38997
TTD 6.787708
TWD 32.944402
TZS 2650.074057
UAH 45.435091
UGX 4147.791748
UYU 40.582868
UZS 12004.176313
VES 912.87925
VND 25764
VUV 120.719595
WST 2.810584
XAF 596.337034
XAG 0.021318
XAU 0.000260262813
XCD 2.70255
XCG 1.801394
XDR 0.707052
XOF 596.337034
XPF 108.275455
YER 236.550076
ZAR 16.993275
ZMK 9001.205356
ZMW 20.4664
ZWL 321.999592
SSP 5945.381189
MXV 2.083467
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025
Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025

Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025

Trial taking place at Sheikh Khalifa Medical City, a flagship United Arab Emirates hospital and largest teaching medical center in Abu Dhabi

Crofelemer, Jaguar's novel plant-based prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both SBS-IF and MVID

Proof-of-concept (POC) data generated from this study could potentially lead to reimbursed early patient access in certain European countries for crofelemer for these rare/orphan diseases

Text size:

SAN FRANCISCO, CA / ACCESS Newswire / February 3, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics today announced that the first short bowel syndrome with intestinal failure (SBS-IF) patient has been dosed in the independent investigator-initiated pediatric POC trial (IIT) of crofelemer, Jaguar's novel plant-based antidiarrheal prescription drug. The first infant with microvillus inclusion disease (MVID) was dosed as part of the same IIT two weeks ago. POC data generated from this study potentially in the first half of 2025 could lead to reimbursed early patient access to crofelemer for these indications in certain European countries.

The trial is being conducted by Dr. Mohamad Miqdady, a recognized leader in pediatric gastroenterology who is the Division Chief of the Pediatric Gastroenterology, Hepatology & Nutrition Division at Sheikh Khalifa Medical City (SKMC), a flagship tertiary hospital in the UAE and the largest teaching medical center in Abu Dhabi.

"Dosing of the SBS-IF first patient in this unblinded study is another important milestone in clinical development efforts for crofelemer for SBS-IF and MVID - both of which are rare and severe diseases requiring intensive parenteral nutrition and support," said Lisa Conte, Jaguar's founder, president, and CEO.

"This study is one of five clinical efforts in rare diseases - three POC IIT studies and two Phase 2 studies - for crofelemer for the orphan disease indications of MVID and/or SBS-IF in the United States, European Union, and/or Middle East and North Africa (MENA) regions," Conte said. "The Company's Phase 2 study to evaluate the efficacy of crofelemer for MVID in pediatric patients has been initiated, as has the independent IIT in the U.S. to evaluate crofelemer for SBS-IF in adults. The two additional studies are expected to initiate in early Q1 2025, with the availability of the first POC IIT result potentially in H1 2025, and with additional POC IIT results expected throughout 2025. In accordance with the guidelines of specific EU countries, published data from clinical investigations in MVID and SBS-IF could support reimbursed early patient access to crofelemer for these debilitating conditions."

SBS-IF and MVID, rare and severe diseases requiring intensive parenteral nutrition and support, have severe morbidity and mortality implications and impact the quality of life of both patients and their caregivers.

SBS affects approximately 10,000 to 20,000 people in the U.S., according to the Crohn's & Colitis Foundation, and it is estimated that the population of SBS patients in Europe is approximately the same size. Pediatric SBS is a malabsorptive condition caused by surgical intestinal resection due to congenital abnormalities, vascular insufficiency or severe inflammatory intestinal disease. The incidence of pediatric SBS varies between 0.02% to 1.2% of live births.1 Based on an estimate of 3.6 million live births in the U.S. in 2023,2 the maximal incidence of pediatric SBS is estimated to be approximately 43,000.

Pediatric SBS-IF is associated with significant morbidity and mortality; and high medical expenses, and the patients also have severe chronic diarrhea. The associated sequelae from chronic diarrhea include significant dehydration, metabolic acidosis or alkalosis, and malnutrition.

MVID is a pediatric disease with an estimated prevalence of a couple of hundred patients globally. It is characterized by severe diarrhea and malabsorption, requiring intensive parenteral support for nutritional and fluid management. Each MVID patient is a unique patient; their journey requires very careful management of their nutritional needs, and there are currently no approved drug treatments for MVID.

The trial is taking place at SKMC. Autosomal recessive disorders and congenital anomalies such as MVID are more prevalent in the MENA region.

Crofelemer has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency for SBS and MVID.

Dr. Miqdady is an Adjunct Professor at Khalifa University's medical school in Abu Dhabi, and serves as a member of Napo's Scientific Advisory Board. He completed his Fellowship in Pediatric Gastroenterology at Baylor College of Medicine and Texas Children's Hospital in Houston.

About Crofelemer

Crofelemer is a novel, oral plant-based prescription medicine purified from the red bark sap, also referred to as "dragon's blood," of the Croton lechleri tree in the Amazon Rainforest. Napo has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for indigenous communities.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that another IIT and another Phase 2 study of crofelemer will initiate in early Q1 2025, Jaguar's expectation that POC data from the IIT in Abu Dhabi may be available in H1 2025, Jaguar's expectation that additional POC IIT results for crofelemer may be available throughout 2025, and Jaguar's expectation that, in accordance with the guidelines of specific EU countries, published data from clinical investigations could support early patient access to crofelemer for SBS-IF or MVID in these countries. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

1 Beth A. Carter, MD, et al. Outcomes from a 12-Week, Open-Label, Multicenter Clinical Trial of Teduglutide in Pediatric Short Bowel Syndrome. The Journal of Pediatrics, 2017; 181:102-11

2 https://www.ncbi.nlm.nih.gov/books/NBK607756/

Contact:

[email protected]

Jaguar-JAGX

SOURCE: Jaguar Health, Inc.



View the original press release on ACCESS Newswire

S.Jordan--TFWP